Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: A haptic feedback system includes movable and static portions coupled by one or more magnetic fields that serve to retard movement of the movable portion with respect to the static portion so as to provide haptic feedback when the movable portion is moved relative to the static portion. A magnet associated with one of the movable and static portions reacts with structure associated with the other of the movable and static portions so as to provide haptic feedback when the movable portion is moved with respect to the static portion.

Abstract: A haptic feedback system includes movable and static portions coupled by one or more magnetic fields that serve to retard movement of the movable portion with respect to the static portion so as to provide haptic feedback when the movable portion is moved relative to the static portion. A magnet associated with one of the movable and static portions reacts with structure associated with the other of the movable and static portions so as to provide haptic feedback when the movable portion is moved with respect to the static portion.

Abstract: A haptic feedback system includes movable and static portions coupled by one or more magnetic fields that serve to retard movement of the movable portion with respect to the static portion so as to provide haptic feedback when the movable portion is moved relative to the static portion. A magnet associated with one of the movable and static portions reacts with structure associated with the other of the movable and static portions so as to provide haptic feedback when the movable portion is moved with respect to the static portion.

Abstract: A haptic feedback system includes movable and static portions coupled by one or more magnetic fields that serve to retard movement of the movable portion with respect to the static portion so as to provide haptic feedback when the movable portion is moved relative to the static portion. A magnet associated with one of the movable and static portions reacts with structure associated with the other of the movable and static portions so as to provide haptic feedback when the movable portion is moved with respect to the static portion.

Abstract: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell.

Abstract: Photodynamic therapy (PDT) is used to stimulate and/or restore hair growth in areas of hair loss. Methods and compositions relating to PDT treatment for alopecia are disclosed. In light of PDT use to remove unwanted hair by inactivating or destroying hair follicles or destroying the tissue feeding the hair follicles, such methods and compositions relate to a surprising and unexpected discovery. PDT permits a means to treat conditions relating to hair loss such as androgenic alopecia, alopecia areata and drug-induced alopecia.

Abstract: The present invention relates to a photodynamic method of treating prostatic disorders such as BPH. The method comprises: (i) delivering photosensitizer directly into prostatic tissue of a patient suffering from or suspected of suffering from a prostatic disorder; and (ii) irradiating the prostatic tissue with a light at a wavelength appropriate to activate the photosensitizer.

Abstract: A cyclonic separation apparatus is described comprising a cylindrical vortex-starting chamber and frusto-conical cyclonic separation chamber. The separation chamber is formed from first and second frusto-conical cyclone regions. The first region has a larger cone-angle than that of the second region for the purpose of reducing the overall axial length of the cyclone separation chamber. A central tubular member extends axially of the cylindrical chamber and comprises a vortex starter. The wider end of the first frusto conical region begins in the region of the downstream end of the central tubular member.

Abstract: A valve closure is described for use in particle separation apparatus. The closure is adapted to move in a direction to make sealing contact with a valve seat to create a closed chamber at the lower end of a frusto-conical cyclone separation chamber in which particles will collect during use. The closure is also adapted to move further in the same direction after sealing engagement has been effected, under the influence of any increase in suction created by restriction of the inlet to the apparatus. This reduces the gap between the downstream end of the frusto-conical cyclone separation chamber and the closure or a member carried by the closure, in response to any increased suction, whilst maintaining the sealed condition. The reduced gap enhances separation during the increased suction. The additional movement of the closure may be effected by providing an O-ring seal which is engaged by the closure to effect the sealing engagement.

Abstract: The present invention relates to a photodynamic method of treating tattoos. The method comprises: (i) intradermally and/or locally delivering photosensitizer into tattooed target tissue; and (ii) irradiating the target tissue with activation energy at a wavelength appropriate to activate the photosensitizer. The present method causes the tattoo inks to fade or disappear completely. In preferred embodiments the tattoo will fade by at least 25%, more preferably at least 50%, even more preferably at least 75%.

Abstract: A inahine for washing and/or cleaning articles comprises a sealable enclosure for containing the articles to which cleaning liquid is to be supplied. The cleaning liquid is heated to a high tomperature and forced into the enclosure under high pressure as finely dispersed or diffused droplets forming a mist or vapour. A pressure greater than atmospheric is maintained in the enclosure to force the cleaning liquid into at least the surface if not through and into the very structure of the material from which the articles are formed, so as to assist the cleaning process by producing a quicker and more efficient sturation of the articles by the cleaning liquid. The latter may comprise water and detergent or a dry-cleaning solvent. The cleaning liquid is removed from the articles and the interior of tbe anclosure by means of a suction pump.

Abstract: The present invention relates to a composition comprising a photosensitizing agent and a skin-penetration enhancer. The composition herein show improved delivery of the photosensitizer through the stratum corneum. In addition, the composition of the present invention show improved stability and a reduced incidence of skin photosensitivity.

Abstract: Particle separation apparatus comprises a cyclone particle separating means, a particle collecting chamber and a fan driven by an electric motor for drawing particle laden air into and through the apparatus. A valve is provided, upstream of the suction fan driving motor and downstream of the cyclone particle separating means, which includes a valve closure and a valve seat against which the closure is normally resiliently urged to prevent air flowing through the valve. The valve is mounted so as to communicate with a passage between the cyclone particle separating means and the fan so that air pressure within the passage acts on one side of the closure while the other side of the closure is exposed to ambient air pressure.

Abstract: An interactive home information system having a node in television communication and data communication with a group of home interface controllers. At each home interface controller, there is a signal input for receiving television signals from the node over a cable television distribution network and a data transceiver for conducting data communications with the node. The node determines whether a home interface controller is requesting interactive service. For each interface controller requesting interactive service, the node assigns a television information signal to the requesting home interface controller. Thus, signal assignment is accomplished on a demand basis for those interface controllers determined to be placed in an interactive mode. Signal assignment may involve selection of a given carrier frequency. Alternatively, signal assignment may involve selection of a time slice.

Abstract: A system (10) has a pipeline (12) comprised of a multi-channel bi-directional video bus (14), multi-channel bi-directional audio bus (16), and a digital interprocessor communications bus (18). The pipeline (12) is equipped with a number of ports (20) where media controller (microprocessor) printed circuit cards (22) can be connected, thus providing a convenient method for connecting media devices (24) to the pipeline (12). In this manner, a media device's video input and output can be optionally connected to any of the video pipes (26) of the video bus (14). Similarly, the media device (24) audio inputs and outputs can be optionally connected to any of the audio bus (16) pipes (26). The switching is accomplished through a pair of analog multiplexers (28) whose connection options have been commanded by local microprocessor (30) resident on the media device microprocessor control board (22).